Apellis Pharmaceuticals hosts conference call on May 7, 2024, to discuss Q1 2024 financials and new complement medicine.

Apellis Pharmaceuticals, a global biopharmaceutical company focused on life-changing therapies for serious diseases, will host a conference call and webcast on May 7, 2024, at 8:30 a.m. ET to discuss its first quarter 2024 financial results. The company has two approved medicines targeting C3 and pioneered a new class of complement medicine in 15 years, including a therapy for geographic atrophy, a leading cause of blindness.